Canntab featured on ABN Newswire

Cannabis Investing News
Cannabis Investing

Canntab Therapeutics recently got featured on ABN Newswire on an article about Queensland Bauxite Ltd half yearly report.

Canntab Therapeutics recently got featured on ABN Newswire on an article about 

VitaCann which is a subsidiary of Medical Cannabis, which is owned by Queensland Bauxite (ASX:QBL),  “entered into an exclusive 50/50 Joint venture partnership with the Canadian Canntab company which has developed a unique world first Cannabis GMP Pharmaceutical Grade Extended Release (XR) pill that comes in a number of formulas intended to treat different illnesses such as chronic pain, anxiety and epilepsy” The article states.

Click here to read the full article.

Click here to connect with Canntab Therapeutics for an Investor Presentation.

 

 

Source: www.abnnewswire.net

The Conversation (0)
×